SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

AGM and Q1 Interim Management Statement

6 Feb 2019 07:00

RNS Number : 1777P
Victrex PLC
06 February 2019
 
 

 

6 February 2019

Victrex plc

AGM and Q1 Interim Management Statement

'Weaker 1st quarter, but H2 opportunity unchanged and continued progress in future growth projects'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its first quarter (Q1) Interim Management Statement ahead of its Annual General Meeting (AGM) being held today.

With expected end-market headwinds, tougher comparatives, some de-stocking and adverse currency, Victrex saw a weaker start to its 2019 financial year. Overall, Q1 revenue of £64.1m was 18% down on the prior year (Q1 2018: £78.7m), with Q1 Group sales volume of 822 tonnes being 22% down on the prior year (Q1 2018: 1,051 tonnes). Excluding volumes for the large Consumer Electronics contract, core business volumes were down approximately 13% during Q1.

Q1 headwinds were predominantly in Automotive and Consumer Electronics markets, principally the ongoing slowdown in Automotive and the associated impact on Value Added Resellers, which sees volumes indirectly supplied to Automotive. As expected, Q1 also saw no volumes supplied for the Large Consumer electronics contract, versus a strong comparative last year.

Pleasingly, January and February saw an improvement, with a notable pick-up in Automotive sales.

Mega-programmes

Our pipeline of new products remains strong. In Gears, we passed advanced prototyping with a major global car manufacturer, ahead of a second, and larger, supply agreement for PEEK based Gears. This opportunity is expected to start in the second half. Whilst cars and light vehicles remain the focus, we have opportunities for PEEK Gears in other modes of transport, with two smaller supply agreements now in place. In our Medical mega-programmes, following submission of the clinical trial for the Knee programme, our partner Maxx Orthopedics is now ready to commence patient recruitment.

Investments for growth

Victrex made two small investments during the period, supporting development of our Polymer & Parts strategy. A small equity investment was made in UK-based Surface Generation Limited, to form a partnership utilising potentially state of the art manufacturing processes, which will support Victrex's mega programmes. The PtFS (Production to Functional Specification) technology offers the potential for enhanced manufacturing effectiveness beyond standard moulding technology, including driving reductions in energy consumption and cycle times required to process the most complex material and part combination.

The Group has also invested in Bond 3D High Performance Technology BV, a Dutch company developing unique, protectable 3D printing (Additive Manufacturing) processes which are capable of producing high strength parts from existing grades of PEEK and PAEK polymers. The investment offers the potential of utilising this technology to help accelerate the market adoption of 3D printed PEEK parts, with particular emphasis on the Medical market.

Financial position

Victrex retains a highly cash generative business model, with no change to its financial position since 30 September 2018. Currency, raw material and energy cost inflation remain modest headwinds for 2019, although these will fall predominantly in the first half.

Outlook

Jakob Sigurdsson, Chief Executive of Victrex, said: "Although Q1 is always the seasonally weakest quarter for Victrex, this quarter has been slightly weaker than anticipated, driven principally by the slowdown in Automotive, the associated impact on Value Added Resellers, and some de-stocking. Q1 also saw expected headwinds in Consumer Electronics, together with strong comparatives and adverse currency.

Pleasingly, January and February saw some initial improvement, although given our Q1 performance, the first half is expected to be much weaker overall, compared to the prior year. Our expectations for the second half are unchanged, with new projects and reduced headwinds supporting our assumptions. With strong structural growth opportunities, a healthy new product pipeline and a highly cash generative business model, we continue to be well-placed for the medium and long term."

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Corporate Communications +44 (0) 7809 595831

Richard Armitage, Group Finance Director +44 (0) 1253 897700

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com

 

Analyst and investor call:

A conference call for analysts and investors will be held this morning at 08.30am GMT. Dial in details +44 (0) 3333 000804 PIN: 49486973#

 

Annual General Meeting:

Victrex will hold its Annual General Meeting at 11.00am this morning, at the offices of JP Morgan Cazenove, 1 John Carpenter Street, London, EC4Y 0JP.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTTAMMTMBBMTBL
Date   Source Headline
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.